Diane M Harper MD MPH MS

Family and Geriatric Medicine Obstetrics and Gynecology Bioengineering Epidemiology and Population Health Health Promotion and Behavioral Sciences

  1. HPV vaccines - A review of the first decade.<http://www.sciencedirect.com/science/article/pii/S0090825817307746>
    Harper DM, DeMars LR. Gynecol Oncol. 2017 Apr 22. pii: S0090-8258(17)30774-6. doi: 10.1016/j.ygyno.2017.04.004. [Epub ahead of print] Review. PMID: 28442134
  2. Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial.<http://www.ncbi.nlm.nih.gov/pubmed/27566633>
    Ramanakumar AV, Naud P, Roteli-Martins CM, de Carvalho NS, de Borba PC, Teixeira JC, Blatter M, Moscicki AB, Harper DM, Romanowski B, Tyring SK, Ramjattan B, Schuind A, Dubin G, Franco EL; HPV-007 Study Group..
    BMJ Open. 2016 Aug 26;6(8):e011371. doi: 10.1136/bmjopen-2016-011371.
  3. Pathways to preterm birth: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.<http://www.ncbi.nlm.nih.gov/pubmed/27491689>
    Harrison MS, Eckert LO, Cutland C, Gravett M, Harper DM, McClure EM, Nunes AP, Lazo S, Moore TM, Watson W, Kochhar S, Goldenberg RL; Brighton Collaboration Pathways to Preterm Birth Working Group. Electronic address: contact@brightoncollaboration.org<mailto:contact@brightoncollaboration.org>..
    Vaccine. 2016 Dec 1;34(49):6093-6101. doi: 10.1016/j.vaccine.2016.03.054. Epub 2016 Aug 1. No abstract available.
  4. Stillbirth: Case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data.<http://www.ncbi.nlm.nih.gov/pubmed/27431422>
    Tavares Da Silva F, Gonik B, McMillan M, Keech C, Dellicour S, Bhange S, Tila M, Harper DM, Woods C, Kawai AT, Kochhar S, Munoz FM; Brighton Collaboration Stillbirth Working Group..
    Vaccine. 2016 Dec 1;34(49):6057-6068. doi: 10.1016/j.vaccine.2016.03.044. Epub 2016 Jul 16. No abstract available.
  5. Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population.<http://www.ncbi.nlm.nih.gov/pubmed/26844141>
    Paynter CA, Van Treeck BJ, Verdenius I, Lau AW, Dhawan T, Lash KA, Bergamini EA, Ekekezie CN, Hilal AM, James KN, Alongi S, Harper SM, Bonham AJ, Baumgartner KB, Baumgartner RN, Harper DM.
    Prev Med Rep. 2015 Jul 31;2:711-6. doi: 10.1016/j.pmedr.2015.07.011. eCollection 2015 Jul 31.
  6. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.<http://www.ncbi.nlm.nih.gov/pubmed/26685704>
    Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, Vallejos C, Minkina G, Pereira Da Silva D, McNeil S, Prilepskaya V, Gogotadze I, Money D, Garland SM, Romanenko V, Harper DM, Levin MJ, Chatterjee A, Geeraerts B, Struyf F, Dubin G, Bozonnat MC, Rosillon D, Baril L; VIVIANE Study Group..
    Int J Cancer. 2016 May 15;138(10):2428-38. doi: 10.1002/ijc.29971.
  7. Incorporating Osteopathic Curriculum Into a Family Medicine Residency.<http://www.ncbi.nlm.nih.gov/pubmed/26545057>
    Hempstead LK, Harper DM.
    Fam Med. 2015 Nov-Dec;47(10):794-8.
  8. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.<http://www.ncbi.nlm.nih.gov/pubmed/26071347>
    Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM; Costa Rica Vaccine Trial Study Group Authors., González P, Jiménez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME; PATRICIA Study Group Authors., Bosch FX, Castellsague X, Chatterjee A, Chow SN, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, Lewis DJ, Limson G, Naud P, Peters K, Poppe WA, Ramjattan B, Romanowski B, Salmeron J, Schwarz TF, Teixeira JC, Tjalma WA; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators.; GSK Vaccines Clinical Study Support Group..
    Lancet Oncol. 2015 Jul;16(7):775-86. doi: 10.1016/S1470-2045(15)00047-9. Epub 2015 Jun 9.
  9. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.<http://www.ncbi.nlm.nih.gov/pubmed/25540273>
    Struyf F, Colau B, Wheeler CM, Naud P, Garland S, Quint W, Chow SN, Salmerón J, Lehtinen M, Del Rosario-Raymundo MR, Paavonen J, Teixeira JC, Germar MJ, Peters K, Skinner SR, Limson G, Castellsagué X, Poppe WA, Ramjattan B, Klein TD, Schwarz TF, Chatterjee A, Tjalma WA, Diaz-Mitoma F, Lewis DJ, Harper DM, Molijn A, van Doorn LJ, David MP, Dubin G; HPV PATRICIA Study Group..
    Clin Vaccine Immunol. 2015 Feb;22(2):235-44. doi: 10.1128/CVI.00457-14. Epub 2014 Dec 24.
  10. In a safety net population HPV4 vaccine adherence worsens as BMI increases.<http://www.ncbi.nlm.nih.gov/pubmed/25076128>
    Harper DM, Else BM, Bartley MJ, Arey AM, Barnett AL, Rosemergey BE, Paynter CA, Verdenius I, Harper SM, Harris GD, Groner JA, Malnar GJ, Wall J, Bonham AJ.
    PLoS One. 2014 Jul 30;9(7):e103172. doi: 10.1371/journal.pone.0103172. eCollection 2014 Jul 30.
  11. Intent to participate in future cervical cancer screenings is lower when satisfaction with the decision to be vaccinated is neutral.<http://www.ncbi.nlm.nih.gov/pubmed/24914536>
    Alexander NM, Harper DM, Comes JC, Smith MS, Heutinck MA, Handley SM, Ahern DA.
    PLoS One. 2014 Jun 10;9(6):e98665. doi: 10.1371/journal.pone.0098665. eCollection 2014 Jun 10. Erratum in: PLoS One. 2014;9(9):e107790.
  12. Women have a preference for their male partner to be HPV vaccinated.<http://www.ncbi.nlm.nih.gov/pubmed/24828237>
    Harper DM, Alexander NM, Ahern DA, Comes JC, Smith MS, Heutinck MA, Handley SM.
    PLoS One. 2014 May 14;9(5):e97119. doi: 10.1371/journal.pone.0097119. eCollection 2014 May 14.
  13. Urban and rural safety net health care system clinics: no disparity in HPV4 vaccine completion rates.<http://www.ncbi.nlm.nih.gov/pubmed/24816199>
    Sandri KJ, Verdenius I, Bartley MJ, Else BM, Paynter CA, Rosemergey BE, Harris GD, Malnar GJ, Harper SM, Griffith RS, Bonham AJ, Harper DM.
    PLoS One. 2014 May 9;9(5):e96277. doi: 10.1371/journal.pone.0096277. eCollection 2014 May 9.
  14. Decadal trends and common dynamics of the bio-optical and thermal characteristics of the African Great Lakes.<http://www.ncbi.nlm.nih.gov/pubmed/24699528>
    Loiselle S, Cózar A, Adgo E, Ballatore T, Chavula G, Descy JP, Harper DM, Kansiime F, Kimirei I, Langenberg V, Ma R, Sarmento H, Odada E.
    PLoS One. 2014 Apr 3;9(4):e93656. doi: 10.1371/journal.pone.0093656. eCollection 2014 Apr 3.
  15. Quantifying the decisional satisfaction to accept or reject the Human Papillomavirus (HPV) vaccine: a preference for cervical cancer prevention.<http://www.ncbi.nlm.nih.gov/pubmed/24551110>
    Harper DM, Irons BB, Alexander NM, Comes JC, Smith MS, Heutinck MA, Handley SM, Ahern DA.
    PLoS One. 2014 Feb 14;9(2):e88493. doi: 10.1371/journal.pone.0088493. eCollection 2014 Feb 14.
  16. Positive high-risk HPV test with negative cytology--a conundrum and blessing of our latest technology.<http://www.ncbi.nlm.nih.gov/pubmed/24420983>
    Harper DM, Groner JA.
    Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):10-1. doi: 10.1158/1055-9965.EPI-13-0708. No abstract available.
  17. Long-term follow-up of HPV16-positive women: persistence of the same genetic variant and low prevalence of variant co-infections.<http://www.ncbi.nlm.nih.gov/pubmed/24244682>
    Geraets DT, van Doorn LJ, Kleter B, Colau B, Harper DM, Quint WG.
    PLoS One. 2013 Nov 11;8(11):e80382. doi: 10.1371/journal.pone.0080382. eCollection 2013 Nov 11.
  18. Quantifying clinical HPV4 dose inefficiencies in a safety net population.<http://www.ncbi.nlm.nih.gov/pubmed/24223131>
    Harper DM, Verdenius I, Ratnaraj F, Arey AM, Rosemergey B, Malnar GJ, Wall J.
    PLoS One. 2013 Nov 6;8(11):e77961. doi: 10.1371/journal.pone.0077961. eCollection 2013 Nov 6.
  19. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.<http://www.ncbi.nlm.nih.gov/pubmed/24092907>
    Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, Chow SN, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, De Carvalho NS, Castro-Sanchez M, Castellsagué X, Poppe WA, De Sutter P, Huh W, Chatterjee A, Tjalma WA, Ackerman RT, Martens M, Papp KA, Bajo-Arenas J, Harper DM, Torné A, David MP, Struyf F, Lehtinen M, Dubin G.
    J Infect Dis. 2013 Nov 1;208(9):1391-6. doi: 10.1093/infdis/jit360.
  20. Predictors of three dose on-time compliance with HPV4 vaccination in a disadvantaged, underserved, safety net population in the US Midwest.<http://www.ncbi.nlm.nih.gov/pubmed/23951123>
    Verdenius I, Harper DM, Harris GD, Griffith RS, Wall J, Hempstead LK, Malnar GJ, Bekkers RL.
    PLoS One. 2013 Aug 8;8(8):e71295. doi: 10.1371/journal.pone.0071295. eCollection 2013 Aug 8.
  21. Sustainable utilization and conservation of plant biodiversity in montane ecosystems: the western Himalayas as a case study.<http://www.ncbi.nlm.nih.gov/pubmed/23825353>
    Khan SM, Page SE, Ahmad H, Harper DM.
    Ann Bot. 2013 Aug;112(3):479-501. doi: 10.1093/aob/mct125. Epub 2013 Jul 3. Review.
  22. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial.<http://www.ncbi.nlm.nih.gov/pubmed/22940493>
    Roset Bahmanyar E, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Skinner SR, Jaisamrarn U, Limson GA, Garland SM, Szarewski A, Romanowski B, Aoki F, Schwarz TF, Poppe WA, De Carvalho NS, Harper DM, Bosch FX, Raillard A, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group..
    Gynecol Oncol. 2012 Dec;127(3):440-50. doi: 10.1016/j.ygyno.2012.08.033. Epub 2012 Aug 30.
  23. 3q26 amplification is an effective negative triage test for LSIL: a historical prospective study.<http://www.ncbi.nlm.nih.gov/pubmed/22792164>
    Heitmann ER, Lankachandra KM, Wall J, Harris GD, McKinney HJ, Jalali GR, Verma Y, Kershnar E, Kilpatrick MW, Tsipouras P, Harper DM.
    PLoS One. 2012;7(7):e39101. doi: 10.1371/journal.pone.0039101. Epub 2012 Jul 6.
  24. Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females.<http://www.ncbi.nlm.nih.gov/pubmed/22111017>
    Harper DM, Vierthaler SL.
    ISRN Obstet Gynecol. 2011;2011:457204. doi: 10.5402/2011/457204. Epub 2011 Nov 2.
  25. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.<http://www.ncbi.nlm.nih.gov/pubmed/21858807>
    Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Hedrick J, Jaisamrarn U, Limson G, Garland S, Romanowski B, Aoki FY, Schwarz TF, Bosch FX, Harper DM, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group..
    Int J Cancer. 2012 Jul 1;131(1):106-16. doi: 10.1002/ijc.26362. Epub 2011 Oct 23.
  26. Management implications of the response of two tilapiine cichlids to long-term changes in lake level, allodiversity and exploitation in an equatorial lake.<http://www.ncbi.nlm.nih.gov/pubmed/21848136>
    Oyugi DO, Harper DM, Ntiba JM, Kisia SM, Britton JR.
    Ambio. 2011 Jul;40(5):469-78.
  27. Review of Gardasil.<http://www.ncbi.nlm.nih.gov/pubmed/23805398>
    Harper DM, Vierthaler SL, Santee JA.
    J Vaccines Vaccin. 2010 Nov 23;1(107). pii: 1000107.
  28. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies.<http://www.ncbi.nlm.nih.gov/pubmed/20670593>
    Harper DM, Williams KB.
    Discov Med. 2010 Jul;10(50):7-17. Review.
  29. Smoking enhances risk for new external genital warts in men.<http://www.ncbi.nlm.nih.gov/pubmed/19440442>
    Wiley DJ, Elashoff D, Masongsong EV, Harper DM, Gylys KH, Silverberg MJ, Cook RL, Johnson-Hill LM.
    Int J Environ Res Public Health. 2009 Mar;6(3):1215-34. doi: 10.3390/ijerph6031215. Epub 2009 Mar 20.
  30. Human papillomavirus and HPV vaccines: a review.<http://www.ncbi.nlm.nih.gov/pubmed/18026629>
    Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, Edmunds WJ, Claeys P, Goldenthal KL, Harper DM, Markowitz L.
    Bull World Health Organ. 2007 Sep;85(9):719-26. Review.
  31. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.<http://www.ncbi.nlm.nih.gov/pubmed/17494926>
    Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators..
    N Engl J Med. 2007 May 10;356(19):1928-43.
  32. Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines.<http://www.ncbi.nlm.nih.gov/pubmed/17428949>
    Garland SM, Steben M, Hernandez-Avila M, Koutsky LA, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Esser MT, Vuocolo SC, Nelson M, Railkar R, Sattler C, Barr E; 012 Study Investigators..
    Clin Vaccine Immunol. 2007 Jun;14(6):792-5. Epub 2007 Apr 11.
  33. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.<http://www.ncbi.nlm.nih.gov/pubmed/16631880>
    Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G; HPV Vaccine Study group..
    Lancet. 2006 Apr 15;367(9518):1247-55.
  34. Why am I scared of HPV?<http://www.ncbi.nlm.nih.gov/pubmed/15371282>
    Harper DM.
    CA Cancer J Clin. 2004 Sep-Oct;54(5):245-7.
  35. Factors affecting the detection rate of human papillomavirus.<http://www.ncbi.nlm.nih.gov/pubmed/15055412>
    Harper DM, Longacre MR, Noll WW, Belloni DR, Cole BF.
    Ann Fam Med. 2003 Nov-Dec;1(4):221-7.